Beijing Tiantan Biological Products Co., Ltd.
600161
Rang in aandelen
#4320
Beijing Tiantan Biological Products Co., Ltd., established in 1998 and... Beijing Tiantan Biological Products Co., Ltd., established in 1998 and headquartered in Beijing, China, is actively involved in the full spectrum of blood product operations within China. This includes pioneering research and development, manufacturing, sales, and providing consultancy services. Its comprehensive product line features critical blood-derived medicines such as intravenous immunoglobulin, human albumin, and various specialized human immunoglobulins for conditions like hepatitis B (both standard and freeze-dried formulations) and tetanus, alongside other general human immunoglobulin preparations and intravenous blood system solutions. The company operates as a subsidiary of China National Biotec Group Company Limited.
Aandeelprijs
$1.81
Marktkapitalisatie
$3.59B
Verandering (1 dag)
-0.90%
Verandering (1 jaar)
-32.39%
Land
CN
Handel Beijing Tiantan Biological Products Co., Ltd. (600161)
Categorie
Healthcare
Winst voor Beijing Tiantan Biological Products Co., Ltd. (600161)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Beijing Tiantan Biological Products Co., Ltd. bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Beijing Tiantan Biological Products Co., Ltd. van 2001 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2025 | $260.52M | -25.35% |
| 2024 | $348.98M | 37.34% |
| 2023 | $254.09M | 22.89% |
| 2022 | $206.77M | 5.90% |
| 2021 | $195.25M | 15.45% |
| 2020 | $169.13M | 12.87% |
| 2019 | $149.85M | 18.76% |
| 2018 | $126.18M | -46.94% |
| 2017 | $237.80M | 345.91% |
| 2016 | $53.33M | 74.97% |
| 2015 | $30.48M | -37.81% |
| 2014 | $49.01M | -45.63% |
| 2013 | $90.14M | 26.29% |
| 2012 | $71.38M | 31.58% |
| 2011 | $54.25M | 32.45% |
| 2010 | $40.96M | -20.34% |
| 2009 | $51.42M | 51.23% |
| 2008 | $34.00M | 38.09% |
| 2007 | $24.62M | 53.52% |
| 2006 | $16.04M | 54.94% |
| 2005 | $10.35M | 53.69% |
| 2004 | $6.73M | 8.91% |
| 2003 | $6.18M | 14.01% |
| 2002 | $5.42M | 10.09% |
| 2001 | $4.93M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $1.95B | - |
NL
|
|
| - | - |
CH
|
